Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPIS - Congenital myopathy intervention study using salbutamol
2024-512027-36-00Phase 4Completed
- Sponsor
- Region Västra Götaland
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of salbutamol in congenital myopathy (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Change in MFM32 score after 6 months of treatment versus no treatment. Started Apr 2024; status: completed.
02
Drugs
salbutamol
03
Conditions
congenital myopathy
Beyond the preview
Go deeper on 2024-512027-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512027-36-00.